ACP supports QPP measure 442: "Persistence of Beta-Blocker Treatment after a Heart Attack." The exclusion criterion is broad and it is appropriate to attribute the measure outcomes to the individual clinician. Additionally, the measure is based on high-quality evidence from the most recent recommendations of various organizations (*ACP, ACC, ACCF/AHA, ESC). While we support this measure, we note the measure is close to being topped out. Data from the 2014 HEDIS reporting period demonstrates an 84% compliance rate.

*American College of Physicians, American College of Cardiology, American College of Cardiology Foundation/American Heart Association, European Society of Cardiology